Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
NCT06890923
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Active Secondary Progressive Multiple Sclerosis
Interventions
DRUG:
Foralumab TZLS-401 100 µg
Sponsor
Tiziana Life Sciences LTD